ES2184881T3 - Composicion farmaceutica de ester etilico de l-dopa. - Google Patents

Composicion farmaceutica de ester etilico de l-dopa.

Info

Publication number
ES2184881T3
ES2184881T3 ES96923037T ES96923037T ES2184881T3 ES 2184881 T3 ES2184881 T3 ES 2184881T3 ES 96923037 T ES96923037 T ES 96923037T ES 96923037 T ES96923037 T ES 96923037T ES 2184881 T3 ES2184881 T3 ES 2184881T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
dopa
ester
ethical
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96923037T
Other languages
English (en)
Inventor
Sasson Cohen
Yoram Sela
Ruth Levy
Nava Shterman
Eldad Melamed
Daphne Atlas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2184881T3 publication Critical patent/ES2184881T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION PROPORCIONA UNA COMPOSICION FARMACEUTICA QUE CONTIENE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE ESTER ETILICO DE L % DE HIDROXIPROPILMETIL CELULOSA, UN 0,25 A 4,5 % DE HIDROXIPROPIL CELULOSA Y UN 1 A 90 % DE UN POLIMERO CARBOXIVINILO.
ES96923037T 1995-07-21 1996-07-18 Composicion farmaceutica de ester etilico de l-dopa. Expired - Lifetime ES2184881T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US136895P 1995-07-21 1995-07-21

Publications (1)

Publication Number Publication Date
ES2184881T3 true ES2184881T3 (es) 2003-04-16

Family

ID=21695690

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96923037T Expired - Lifetime ES2184881T3 (es) 1995-07-21 1996-07-18 Composicion farmaceutica de ester etilico de l-dopa.

Country Status (12)

Country Link
US (1) US5840756A (es)
EP (1) EP0840603B1 (es)
JP (1) JPH11509547A (es)
AT (1) ATE223712T1 (es)
AU (1) AU6368596A (es)
CA (1) CA2227208A1 (es)
DE (1) DE69623634T2 (es)
DK (1) DK0840603T3 (es)
ES (1) ES2184881T3 (es)
IL (1) IL123010A (es)
PT (1) PT840603E (es)
WO (1) WO1997003662A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512027A (en) * 1998-11-10 2004-04-30 Teva Pharma Dispersible compositions containing L-dopa ethyl ester
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
GB0114198D0 (en) * 2001-06-11 2001-08-01 Syngenta Ltd Herbicidal composition
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
AU2002346372A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
WO2003041646A2 (en) 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
KR20080109101A (ko) * 2003-10-20 2008-12-16 테바 파마슈티컬 인더스트리즈 리미티드 레보도파의 지속적 효과를 위한 조성물 및 제형
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
MX2007011976A (es) * 2005-03-28 2007-12-07 Orexo Ab Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson.
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CN101910113A (zh) 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2025075499A1 (en) 2023-10-02 2025-04-10 Universiteit Van Amsterdam Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil.
GB2644236A (en) 2024-09-24 2026-03-25 Novumgen Ltd Orodispersible tablet composition containing carbidopa and levodopa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease

Also Published As

Publication number Publication date
EP0840603B1 (en) 2002-09-11
EP0840603A1 (en) 1998-05-13
IL123010A (en) 2003-11-23
ATE223712T1 (de) 2002-09-15
PT840603E (pt) 2003-01-31
CA2227208A1 (en) 1997-02-06
IL123010A0 (en) 1998-08-16
DE69623634D1 (de) 2002-10-17
DE69623634T2 (de) 2003-05-22
DK0840603T3 (da) 2003-01-20
JPH11509547A (ja) 1999-08-24
AU6368596A (en) 1997-02-18
US5840756A (en) 1998-11-24
WO1997003662A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
ES2184881T3 (es) Composicion farmaceutica de ester etilico de l-dopa.
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
TR199700660T1 (xx) Yeni farnezil transferaz �nleyiciler.
SE9504661D0 (sv) New compounds
RU95108590A (ru) Производные имидазола
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
RU95106674A (ru) Полиеновые соединения, фармацевтическая и косметическая композиция на их основе
DE69637964D1 (de) Derivaten von Nodulisporen Säure
BR9609653A (pt) Compostos e composições farmacêuticas contendo os mesmos
ES2173858T3 (es) Analogos de huperzina a.
UA42819C2 (uk) Ін`єкційний та інфузійний розчин, що містить енрофлокcацин
DE69616074D1 (de) Ara-c derivate
PY0101314A (es) Compuestos farmaceuticos
BR9611472A (pt) Compostos de di-terc-butilfenol contendo enxofre úteis como agentes antiinflamatórios
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
BR9813102A (pt) Derivados de ácido metilenobisfosfÈnico novos
TR200002293T2 (tr) Farmasötik bileşimler.
YU49316B (sh) Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
AU6832498A (en) Substituted benzyl oximino compounds
ATE206431T1 (de) Antifungal fusacandine
AU5994796A (en) Modified kojibiosides analogues
FR2732604B1 (fr) Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant